can be modified by activation of protein kinase C (PKC). However, the effect of PKC activation on I Ca is still controversial. Some studies have shown a decrease in current, whereas other studies have reported a biphasic effect (an increase followed by a decrease in current or vice versa). A possible explanation for the conflicting results is that several isoforms of PKC with opposing effects on ICa were activated simultaneously. Here, we examined the influence of a single PKC isoform (PKC-␤II) on L-type calcium channels in isolation from other cardiac isoforms, using a transgenic mouse that conditionally expresses PKC-␤II. Ventricular cardiac myocytes were isolated from newborn mice and examined for expression of the transgene using single cell RT-PCR after ICa recording. Cells expressing PKC-␤II showed a twofold increase in nifedipine-sensitive ICa. The PKC-␤II antagonist LY-379196 returned ICa amplitude to levels found in non-PKC-␤II-expressing myocytes. The increase in ICa was independent of Cav1.2-subunit mRNA levels as determined by quantitative RT-PCR. Thus these data demonstrate that PKC-␤ is a potent modulator of cardiac L-type calcium channels and that this specific isoform increases ICa in neonatal ventricular myocytes. second messengers; signal transduction CALCIUM IS AN IMPORTANT COMPONENT of several signaling cascades and subserves numerous cellular functions. In cardiac cells, a small influx of calcium quickly increases the free intracellular concentration by promoting calcium release from the sarcoplasmic reticulum. This process has been called calcium-induced calcium release and mediates the excitation-contraction coupling mechanism in the heart. Alteration of calcium regulation potentially perturbs excitation-contraction coupling, which may manifest as altered contractility. Furthermore, second messenger systems that are altered in cardiac disease may modify the L-type calcium channel properties to elevate intracellular calcium levels and activate calcium-sensitive signaling pathways. Several classes of protein kinases, especially protein kinase A (PKA), modulate voltage-gated calcium channels to enhance calcium influx (11, 14, 16, 17) . The protein kinase C (PKC) signaling cascade may also play a central role in the regulation of calcium channels in a number of cell types, including cardiac myocytes (7, 12). However, results from studies (4, 24) examining the effects of PKC on cardiac calcium channels are contradictory, likely reflecting physiological and technical limitations. For example, studies that utilize cell expression systems reconstitute channel proteins outside their native environment and thereby diminish their physiological relevance. In addition, the use of nonselective PKC activators such as phorbol esters, either in cardiac cells or expression systems, activates multiple PKC isoforms and thereby obscures PKC isoform-specific functions. The typical response to PKC activation in expression systems is an initial increase followed by a decrease in current (4, (18) (19) (20) , although other studies (13) report only a reduction of the current. Similarly, experiments using isolated cardiac cells have shown a biphasic response of the calcium current (I Ca ) to PKC activation with an initial increase followed by a decrease (3) or a decrease followed by an increase (24). In other experiments using cardiac cells, a PKC-mediated increase of I Ca (1) or a phorbol ester-induced decrease in current (23) has been observed. Reduction of I Ca induced by phorbol esters was attenuated by the addition of peptide inhibitors of the C2 region of PKC isoforms (␣, ␤I, ␤II), suggesting that these isozymes are linked to channel inhibition (23). However, Asai et al. (2) suggested that some of the attenuation of I Ca in cardiac myocytes may be due to a direct effect of phorbol esters on calcium channels and may be independent of PKC activity.
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In the absence of consensus regarding the effect of specific PKC isoforms on L-type calcium channel function, we studied the modulation of calcium channels by a single PKC isozyme (PKC-␤II) in a relevant physiological environment, neonatal cardiocytes. We used a conditional binary transgenic mouse model that expresses modest levels of constitutively active PKC-␤II (5) while all the other PKC isoforms remain inactive. The expression of PKC-␤II is restricted to the heart and can be temporally regulated by oral tetracycline. We found that PKC-␤II substantially increased L-type I Ca in cardiac cells. Current enhancement was blocked by a selective PKC-␤II inhibitor, supporting the idea that activation of this PKC isoform has a positive effect on I Ca . The levels of Ca v 1.2 subunit mRNA were similar in PKC-␤II-expressing and non-PKC-␤II-expressing cells, suggesting that PKC-␤II exerted a direct effect on the calcium channel.
METHODS
The experiments were approved by the Animal Care and Use Committee of the University of Illinois at Chicago and followed the guidelines of the National Institutes of Health. We used the tetracycline transactivator only (tTA)/ PKC-␤II mouse, in which expression of a constitutively active PKC-␤II can be induced by removal of tetracycline from the drinking water (5) . In this transgenic mouse, the PKC-␤II isoform is rendered active by an internal deletion of the pseudosubstrate domain. To permit expression during fetal development, tetracycline was not placed in maternal drinking water.
Genomic diagnosis of PKC-␤II transgenic mice. A small section of tail (ϳ5 mm) was cut from individual newborn mice (Ͻ24 h old) to isolate DNA, using a commercial kit (DNeasy tissue kit, Qiagen). PCR was performed on the DNA eluate with AmpliTaq DNA polymerase (Perkin Elmer) and genespecific primers. Four different genotypes were determined on the basis of a heterozygote cross: wild type (WT), (tTA/ PKC-␤II Ϫ/Ϫ); tTA, (tTA/PKC-␤II ϩ/Ϫ); PKC-␤II only (PKC-␤II), (tTA/PKC-␤II Ϫ/ϩ); and binary (tTA/PKC-␤II ϩ/ϩ). The genotype of individual animals was established both by Southern blotting and PCR as previously described (5) . Because expression of PKC-␤II in this transgenic mouse requires the presence of both the tTA and PKC-␤II transgenes (binary), the PKC-␤II only group, which is missing the tTA transgene, was not included in this study.
Cell isolation. Primary cultures were prepared from cardiac muscle of newborn mice at postnatal day 0. Mice were anesthetized by methoxyflurane inhalation and decapitated. The hearts were removed, and the ventricles were isolated and finely minced. The small pieces of muscle were incubated at 37°C for 30 min in Ca 2ϩ , Mg 2ϩ -free rodent Ringer composed of 155 mM NaCl, 5 mM KCl, 11 mM glucose, and 10 mM HEPES, pH 7.4, containing 1 mg/ml collagenase type IA (Sigma). Dissociated muscle was triturated with a Pasteur pipette in culture medium (vol/vol, 90% DMEM with 4.5 g/l glucose and 10% horse serum). Large debris was removed from the solution by filtration and centrifugation, and a suspension of single myocytes was obtained. Each heart was dissociated individually, and the cells obtained from one heart were plated on two 35-mm culture dishes. Cultures were maintained in a 37°C incubator with a mixture of air and 5% CO 2.
ICa measurements. ICa was measured using the whole cell configuration of the patch-clamp technique (8) . Membrane linear components were digitally subtracted by appropriate scaling of the average of eight hyperpolarizing current records elicited from Ϫ80 mV. I Ca were elicited with 250-ms test pulses, which were preceded by a 1-s prepulse to Ϫ50 mV to inactivate T-type and sodium currents. Recording electrodes were filled with a solution containing (in mM) 140 cesium aspartate, 5 MgCl 2, 2.5 Mg ATP, 0.5 Tris GTP, 10 Cs2 EGTA, and 10 HEPES (pH 7.2 adjusted with CsOH). The recording solution contained (in mM) 145 tetraethylammonium chloride, 10 CaCl 2, 10 HEPES, and 0.001 TTX, pH 7.4 adjusted with CsOH. Membrane capacitance was measured by integrating the area under the capacity transient before series resistance compensation. To normalize for differences in total membrane area, current densities (in pA/pF) were calculated by dividing the total current by the membrane capacitance of the cell. Data acquisition and processing were performed with pClamp 7.0 software (Axon Instruments).
The current-voltage relationship from a single cell was fit to the equation
where G max is the maximum conductance, V is the membrane potential, V rev is the reversal potential, V 1 ⁄2 is the half-activation potential, and k is the slope.
PKC-␤ inhibitors. Cultured ventricular myocytes were incubated with an inhibitor of PKC-␤, LY-379196 (Lilly Laboratories, Indianapolis, IN), for 1 h before patch-clamp experiments. LY-379196 was used at a concentration of 30 nM and was also present in the extracellular recording solution. Previous experiments (9, 10, 21) have demonstrated a selective and adequate inhibition of this particular enzyme isoform with these compounds. LY-379196 is highly selective for PKC-␤ and shows nonspecific PKC inhibition only at concentrations 20 times higher than the one used here. At 600 nM, LY-379196 blocks the ␣ and ␥ isoforms, and even higher concentrations are needed to block other PKC isoforms (9, 10) .
Single cell RT-PCR. The 3Ј-end amplification RT-PCR technique was applied to single cells and used to detect transgene expression. The 3Ј-end amplification-PCR protocol was previously described (6) and used in this study with minor modifications. To confirm the expression of PKC-␤II, cytoplasm from a single ventricular myocyte was aspirated by mechanical suction into the patch-clamp electrode following current recordings. The contents of the pipette were placed into a sterile PCR tube containing the reverse transcription reactants (without the enzyme) and frozen in liquid nitrogen before the RT reaction. Gene-specific PCR was carried out using 10 l of the amplified cDNA in a 25 l volume with 1ϫ PCR buffer, 2 mM MgCl2, 1 mM dNTP, 0.625 U Taq DNA polymerase (Life Technologies), and 100 ng of each primer. PCR products were visualized on a 2% agarose gel and subcloned into pCRII-TOPO (Invitrogen) for sequencing to confirm the amplification of a specific product.
Quantitative RT-PCR. To determine the level of expression of various genes, real-time quantitative RT-PCR with SYBR Green detection was performed using a LightCycler thermocycler (Roche Diagnostics). Total RNA was extracted from transgenic and WT neonatal (day 1) hearts using TRIzol (Life Technologies), and a total of 100 ng was used in each RT-PCR reaction. The RT-PCR reaction was quantified on the basis of a series of in vitro transcribed mRNA standards prepared for each gene that were analyzed and run alongside to develop a standard curve. A one-step RT-PCR reaction using the RNA amplification kit with SYBR Green1 (Roche Molecular Biochemical) was used to analyze gene expression. The reaction conditions for RT were 55°C for 15 min, which was followed by a four-step PCR amplification with signal acquisition at 80-89°C for 2 s (depending on the Tm for each PCR product determined by melting curve analysis) for 45 cycles. The second derivative maximum (log linear phase) for each amplification curve was determined and plotted against the standard curve to calculate the amount of product. Samples were normalized against glyceraldehyde-3-phosphate dehy-drogenase (GAPDH) expression to ensure equal loading. The following primers were used: PKC-␤II (bovine), forward AT-GGCTGACCCGGCCG and reverse CTAAATGTTTCGTTC-CACTCGGGG (GenBank M13974); ␣-myosin heavy chain (␣-MHC), AAGGTGAAGGCCTACAAGCG and TTTCTGC-TGGACAGGTTATTCC (M76601); ␤-myosin heavy chain (␤-MHC), AAGGTGAAGGCCTACAAGCG and TTCTGCT-TCCACCTAAAGGGC (M74752); GAPDH, TATGACAAT-GAATACGGCT and CTCCTGTTATTATGGGGG (M32599); and Ca v1.2 subunit, GAAATTCAAGAAGCGAAAG and CCT-GCTGTCACTCTGATAGTAG (NM009781).
Statistics. Data are expressed as means Ϯ SE. I Ca was analyzed using ANOVA with repeated measures (Statistica 5.1, StatSoft, Tulsa, OK). RNA data are reported as means Ϯ SE. Comparisons among groups were determined by ANOVA followed by post hoc analysis with the Student-NewmanKeuls test. P Ͻ 0.05 was considered to be significant.
RESULTS
Single cell RT-PCR. Individual ventricular myocytes were examined for the presence of the PKC-␤II transgene to confirm the genomic diagnosis of the mouse from which the cells were isolated. The single cell analysis was performed because there is heterogeneity of expression in the hearts of transgenic mice, particularly in the neonatal mice with the oral tetracyclineoff system of gene regulation (22) .
Cytoplasm from individual myocytes was aspirated into the patch pipette for RT-PCR immediately after I Ca recording. To determine the effects of PKC-␤II on I Ca , we compared only PKC-␤II-expressing cells with the groups that did not contain the PKC transgene (WT and tTA). Concurrent with the detection of PKC-␤II, we used ␣-and ␤-MHC mRNA as a selection criterion for the successful completion of the single cell RT-PCR procedure. Figure 1 shows the results obtained with this screening technique from a tTA and a PKC-␤II-expressing ventricular myocyte. All cells screened expressed the ␣-and ␤-MHC mRNA independently of PKC-␤II expression. Cells in which PKC-␤II expression was uncertain, regardless of the presence of ␣-or ␤-MHC, were not included in this study.
I Ca measurement in neonatal cells. L-type I Ca were recorded 24-48 h after ventricular myocytes were plated. Data from tTA and WT mice were not statistically different and therefore were pooled and denoted as tTA/WT. The maximum I Ca at each V was measured, and a current-voltage relationship was constructed (Fig. 2) . In PKC-␤II-expressing cells, there was a significantly enhanced I Ca density at V from Ϫ30 to 60 mV compared with tTA/WT cells (Fig. 2, A and B To verify the nature of the current increased by PKC-␤II, we measured I Ca in PKC-␤II-expressing cells before and after the addition of the specific calcium channel blocker nifedipine. I Ca from a PKC-␤II expressing cell is shown in Fig. 2C before and after perfusion with nifedipine in the extracellular recording solution. When cells were depolarized from a holding potential of Ϫ80 mV, 10 M nifedipine caused a significant reduction of I Ca . This result was confirmed in eight additional cells. Nifedipine block of I Ca was larger in two of these cells when they were depolarized using a 1-s prepulse to Ϫ50 mV (Fig. 2C) . The average current-voltage curve for all cells before and after nifedipine treatment is shown in Fig. 2D . Thus modulation of the L-type calcium channel was responsible for the large increase in current density observed in PKC-␤II-expressing cells.
PKC-␤II inhibition restores I Ca amplitude to control levels.
To further confirm that PKC-␤II enhanced the L-type I Ca , we exposed PKC-␤II-expressing cells to a selective PKC-␤ inhibitor, LY-379196, before patchclamp experiments. LY-379196 (30 nM) was also maintained in the extracellular recording solution as described previously (9, 10, 21) . As shown in Fig. 3A , LY-379196 had no significant effects on tTA/WT cells, which suggests minimal L-type calcium channel activation by PKC-␤ in these cells. The lack of an effect of the drug on I Ca amplitude in tTA/WT cells also underscores the isoform specificity of the agent, since other isoforms of PKC (such as PKC-␦) have some basal activity in the absence of agonist stimulation. On the other hand, we observed a significant attenuation of I Ca density in PKC-␤II-expressing cells with LY-379196 (Fig. 3B) . The remaining I Ca in PKC-␤II-expressing cells was identical to tTA/WT cells after expo- Fig. 1 . Gene expression analysis by single-cell RT-PCR. A: expression of the myosin heavy chain (MHC) genes (␣-and ␤-MHC) in an individual myocyte isolated from a tetracycline transactivator only (tTA) heart. Note the lack of protein kinase C-␤II (PKC-␤II) transgene expression. The same results were found when wild-type (WT) myocytes were examined. B: analysis of a myocyte isolated from a binary mouse, which contained the PKC-␤II transgene and the 2 muscle genes ␣-MHC and ␤-MHC. Cytoplasm of single myocytes was aspirated after recording of calcium currents (ICa), and mRNA was detected using the 3Ј-end amplification RT-PCR method.
sure to LY-379196 (Fig. 3C) . The rapid inhibition of I Ca with LY-379196 strongly supports the idea that the augmented I Ca observed in PKC-␤II-expressing cells was due to phosphorylation of the L-type calcium channel.
Quantitative gene expression. Quantitative real time RT-PCR was performed on RNA extracted from neona- Fig. 2 . ICa in neonatal PKC-␤II and tTA/WT cells. A: ICa records from a representative tTA/WT cell and a PKC-␤II-expressing cell. Currents shown correspond to membrane potentials from Ϫ30 to 60 mV and were elicited using the prepulse protocol. B: maximum ICa densities obtained from PKC-␤II-expressing cells (}) (n ϭ 16) were greater compared with tTA/WT cells (OE) (n ϭ 22) at membrane potentials from Ϫ30 to 60 mV. * P Ͻ 0.05, significantly different from tTA/WT cells. C: ICa records from a PKC-␤II-expressing cell before and after treatment with the L-type channel blocker nifedipine (10 M). Currents were elicited at Ϫ30 to 60 mV from a holding potential (Vh) of Ϫ80 mV. ICa was significantly reduced in the presence of nifedipine from Ϫ80 mV. ICa was completely abolished when test pulses were preceded by a prepulse to Ϫ50 mV as shown by the lower records at right, which correspond to a different cell. D: currentvoltage relationship of PKC-␤II cells before (}) (n ϭ 9) and after nifedipine perfusion (OE) (n ϭ 9). Currents used in the graph were elicited from Ϫ80 mV. * P Ͻ 0.05, significantly different from untreated cells. tal hearts to determine whether the enhanced calcium influx seen in the PKC-␤II cells was correlated with an increased L-type calcium channel expression. We measured the levels of the Ca v 1.2 subunit (the pore-forming subunit) of the L-type calcium channel along with ␣-MHC, ␤-MHC, and GAPDH in the same preparation. Similarly to the single cell analysis, ␣-and ␤-MHC were included in this screening to serve as internal controls. GAPDH was used to normalize the level of expression of the other three genes. The results of this analysis are shown in Fig. 4 . The amount of Ca v 1.2 subunit was 15.3 Ϯ 3.73 fg/pg GAPDH (n ϭ 5) in tTA/WT hearts and 20.8 Ϯ 7.95 fg/pg GAPDH (n ϭ 5) in PKC-␤II hearts (Fig. 4A) . This difference was not statistically significant. This result suggests that the number of calcium channels remained constant and further supports the idea that the increase in current in neonatal cells was due to phosphorylation of the calcium channel.
The levels of ␣-and ␤-MHC were also similar between tTA/WT and PKC-␤II neonatal hearts (Fig. 4B) . The levels of ␣-MHC were 0.27 Ϯ 0.04 pg/pg GAPDH (n ϭ 5) in tTA/WT mice and 0.46 Ϯ 0.12 pg/pg GAPDH (n ϭ 5) in PKC-␤II mice. ␤-MHC levels were 2.18 Ϯ 0.46 pg/pg GAPDH (n ϭ 5) in tTA/WT mice and 1.56 Ϯ 0.69 pg/pg GAPDH (n ϭ 5) in PKC-␤II mice. In both tTA/WT and PKC-␤II mice, the amounts of ␤-MHC were significantly higher than the levels of ␣-MHC. The embryonic isoform (␤-MHC) is expressed at the highest levels during embryonic development and then declines during postnatal development, when ␣-MHC predominates. We found significantly higher levels of ␤-MHC expression compared with ␣-MHC, which is probably indicative of the very early stages of postnatal development (Ͻ24 h old) when the myocytes were isolated.
DISCUSSION
The results of our study clearly show that expression of constitutively active PKC-␤II in neonatal cardiac myocytes enhances the L-type I Ca . Furthermore, the stimulatory effect of PKC-␤II was completely blocked by the addition of the specific PKC-␤ antagonist LY-379196. Our data also show that the I Ca increase was independent of changes in the level of Ca v 1.2 subunit mRNA, suggesting that PKC-␤II exerts its effect directly on the calcium channel.
Numerous studies (1-5, 12, 13, 18-20, 23, 24) have examined the modulation of the cardiac L-type calcium channel by PKC activation, either in heterologous expression systems or in native cells. However, the experiments have produced conflicting data, and there is no consensus as to the effect of PKC on calcium channels. This apparent controversy may be explained by the use of cell expression systems or models in which nonspecific PKC activation or inhibition was employed; this is not an issue in the novel transgenic model system we have used here.
Detailed biochemical information regarding regulation of these channels by phosphorylation is quite limited because they are complex multimeric membrane proteins and difficult to study in native tissues. In addition, it is not known whether one or more of the channel proteins are directly phosphorylated by PKC or whether the observed alterations in channel function are the result of secondary activation of another downstream effector(s). Presently, both the Ca v 1.2 and ␤ subunits are considered to be possible substrates for PKC-dependent phosphorylation in vitro (15, 18) . The Ca v 1.2 subunit in particular has been examined for putative phosphorylation sites, and several have been recognized. Regulation by PKC could occur through either direct phosphorylation of one or more of the channel proteins or indirect phosphorylation of another downstream effector(s) that might alter channel kinetics and behavior. Alternatively, PKC could modify transcriptional or posttranslational aspects of L-type calcium channel expression to bring about changes in the number of channels within the membrane that would also alter channel kinetics and behavior. Therefore, to detail some of the biochemical information regarding L-type calcium channel regulation, we analyzed channel activity and correlated this with the expression of Ca v 1.2 subunit mRNA as an index of channel number in response to PKC-␤II activation.
The data presented here suggest that PKC-␤II modulates cardiac L-type calcium channels via posttranslational mechanisms. This conclusion is supported by a Fig. 4 . Quantification of gene expression by real-time RT-PCR. A: expression of the Cav1.2 subunit of the L-type calcium channel in whole hearts of neonatal tTA/WT and PKC-␤II mice showed no significant difference. B: the expression level of the ␣-and ␤-MHC isoforms was similar in tTA/WT and PKC-␤II mice. Expression of ␤-MHC was significantly higher than the expression of ␣-MHC in either group. Determination of mRNA levels was performed in 5 hearts for each group. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. * P Ͻ 0.05, significantly different from ␣-MHC. number of observations. Foremost is the return of I Ca in PKC-␤II-expressing cells treated with LY-379196 to levels similar to those in tTA/WT cells during a short incubation. If a greater number of channels were responsible for the increased I Ca , then upon inhibition the I Ca in the PKC-␤II-expressing cells might still be greater than in the tTA/WT cells. It is unlikely, though not impossible, that the PKC effect is due to an increase in channel number. In conflict with this possibility is the fact that, at this developmental stage, the transgene would have only been expressed for ϳ3-4 days in the ventricular myocytes by virtue of the ␣-MHC promoter used to drive transgene expression and the mRNA data that document equivalent levels of the Ca v 1.2 subunit mRNA in transgenic and WT neonatal hearts. It is possible that the quantitative mRNA data obtained from the whole heart may reflect the mean level of Ca v 1.2 subunit expression. Therefore, it is still to be determined whether there are changes in the Ca v 1.2 subunit (or other subunits) mRNA expression in individual myocytes expressing the PKC-␤II transgene. Although we recognize that mRNA levels do not always correlate with protein expression, these data strongly suggest that PKC-␤II is capable of altering channel activity independent of an increase in channel number.
The present findings should be qualified by noting that studies were done in neonatal cells, which have immature mechanisms to regulate calcium homeostasis, specifically an undeveloped sarcoplasmic reticulum and lower levels of L-type calcium channel mRNA. While there is no reason to believe that the fundamental biology differs in the adult, in fact the presence of a mature sarcoplasmic reticulum and differences in gene or protein expression of the L-type calcium channel might certainly influence the acquired cardiac phenotype.
In summary, our data provide evidence that constitutively active PKC-␤II modifies the L-type calcium channel to enhance the current. The exact nature of the mechanism is yet to be determined, but the initial evidence suggests the possibility of channel posttranslational modification in neonatal cardiac myocytes. However, as presented here, the combination of these electrophysiological, molecular, and pharmacological techniques should allow for further dissection of the independent actions of these signaling molecules and their isoforms within individual myocytes.
